Pt Jayamas Medica Industri Tbk · IDX:OMED
Pt Jayamas Medica Industri Tbk — Investor Presentation (October 2025)
28 slides from Pt Jayamas Medica Industri Tbk's investor presentation, October 2025
Slide 1: PT Jayamas Medica Industri Tbk (OMED IJ) Company Update 9M 2025
PT Jayamas Medica Industri Tbk (OMED IJ) Company Update 9M 2025 October 2025
Slide 2: Table of Contents
Table of Contents 0 Executive Summary 1 Company Overview 2 Business Overview 3 Key Investment Highlights 4 Growth Strategies 5 Financials & Operations 6 Corporate Highlights & Public Engagements
Slide 3: Executive Summary
EXECUTIVE SUMMARY
Slide 4: Executive Summary
EXECUTIVE SUMMARY PT Jayamas Medica Industri Tbk (OMED or “The Company”) founded in early 2000s. Since then, OMED has become a market leader in the Indonesian medical equipment and supplies market with a diverse product offering product portfolio consists of around 3,550 Active SKUs, supported by a
Slide 5: Company Overview
COMPANY OVERVIEW
Slide 6: Management Profile
Management Profile Board of Commissioners Dr. Yacobus Jemmy Hartanto, MPH Siane Soetanto David A. Worth President Commissioner Commissioner Independent Commissioner Years of Experience: 44 Years of Experience: 38 Years of Experience: 41 Universitas Mahidol Udayana University Dr. Jemmy Hartanto is th
Slide 7: Shareholders Structure
Shareholders Structure Treasury Dr. Jemmy Hartanto, MPH Siane Soetanto Public Shares Shares 50.00% 50.00% PT Intisumber Hasilsempurna – IHS 83.30% 0.93% 0.90% 14.75% 0,12% PT Jayamas Medica Industri Tbk – JMI (M edical Equipm ent & Supplies M anufacturer) *Listed Company 51.00% 99.00% PT Jayamas Wel
Slide 8: Key Milestones
Key Milestones Our Key Accomplishment Since 1992 1992 2000 2002 2006 2016 2022 2023 2024 - Present VENTURED KRIAN GROUND JOINT Total Area Distribution 2,200 sqm BREAKING VENTURES Business New Facility with Foreign Entities Batang, Central Java KRIAN EXPANSION Total Area 8,000 sqm MOJOAGUNG IPO EXPAN
Slide 9: Business Overview
BUSINESS OVERVIEW
Slide 10: Product Portfolio
Product Portfolio Sales by Products – 9M 2025 Antiseptic & Dialysis 11.1% Includes liquid antiseptics 16.3% and disinfectants, dialysis 11.3% fluid, swabs and antiseptic wipes and gel 5.2% Diagnostic & Equipment 4.9% Includes thermometers, digital and manual tensimeters, weight scales and others 2.0
Slide 11: Product Portfolio
Product Portfolio Sales by Products – 9M 2025 (Top 5 in Medical Disposable & Consumables) Infus Set & IV Underpad 7,0% 6,8% Syringe & Needles 22,5% Masks 9,4% Others Gloves 26,7% 27,6%
Slide 12: Production Facility
Production Facility KRIAN FACILITY MOJOAGUNG FACILITY BATANG FACILITY Krian Mojoagung Batang Year of Commencing 2002 2016 2024 Manufacturing Facilities 21,000 Sqm 67,846 Sqm 35,650 Sqm Location East Java Central Java ISO 13485 ISO 9001 ISO 13485 ISO 9001 Quality Quality Quality Quality ISO Managemen
Slide 13: Prominent Customer Profile
Prominent Customer Profile Our Major Global Customer & Revenue Contribution Each Segment 9M 2025 PRIVATE 69.2% GOVERNMENT 30.4% 0.4% EXPORT OneMed’s Diversified Revenue Structure Reflects Low Concentration Risk and Resilient Business Fundamentals
Slide 14: Revenue Channels
Revenue Channels Sales by Brands Sales by Channel Merek OneMed Government Medical Retail Distributors bodies and Facilities customers entities Distributor with e- Supplies all product Catalogue permits are for hospitals able to on-sell to Supply of primarily government, while blood collection
Slide 15: Key Investment Highlight
KEY INVESTMENT HIGHLIGHT
Slide 16: Competitive Advantages
Competitive Advantages ONE STOP SHOPPING DIVERSE SALES CHANNELS 7 Product Categories Approximately 3,550 Active SKUs Retail Distributors Customers Medical Government Facilities Entities EXTENSIVE DISTRIBUTION MANUFACTURING DIVISION 1 National Distribution Center 12 Sales Offices >40% Locally Manufac
Slide 17: Main Competitors' Brand
Main Competitors’ Brand TOP- SELLING Company B Company C Company D Company E Company F Company G Company H Company I Company J PRODUCTS Face Mask Pregnancy Test Gauze & Woundcare Piston Syringe Antiseptic Disinfectant
Slide 18: Growth Strategies
GROWTH STRATEGIES
Slide 19: Capacity and Market Expansion
Capacity and Market Expansion KRIAN BATANG MOJOAGUNG Estimated Budget Use of Proceed Business Expansion Plan Details (IDR Billion) (IDR Billion)* Construction of Buildings, Procurement of Production Machinery New buildings in Batang, new office building in IDR 425 IDR 301 and Equipment Mojoagung, ne
Slide 20: Global Partnership (Export)
Global Partnership (Export) Riding Southeast Asia’s Export Momentum to the U.S. Level Playing Field = New Opportunity Strategic Tailwinds • As of August 2025, the U.S. now applies a uniform 19% • U.S. buyers are diversifying away from China, turning tariff to major Southeast Asian exporters: Indones
Slide 21: Leveraging the C+1 (China +1) to Expand Global Reach
Leveraging the C +1 (China +1) to Expand Global Reach American companies are diversifying supply chains beyond China to reduce geopolitical risks. Southeast Asia, including Indonesia, is emerging as a key beneficiary of this shift. C+1 (CHINA +1) STRATEGY OVERVIEW POSITIVE IMPACT ON ONEMED o America
Slide 22: Financial & Operations
FINANCIAL & OPERATIONS
Slide 23: Financial Overview
Financial Overview Revenue (In Billion Rupiah) EBITDA (In Billion Rupiah) Net Profit (In Billion Rupiah) 1,886 7.7% 1,739 1,737 1,470 1,364 25.0% 21.6% 21.4% 21.6% 16.8% 17.2% 17.4% 20.7% 15.6% 14.9% 434.6 359.5 407.3 290.5 259.4 324.0 291.9 317.5 212.6 255.8 2022 2023 2024 9M24 9M25 2022 2023 2024
Slide 24: Operational Highlight
Operational Highlight Production Price Sales (in thousand units) 9M24 9M25 YoY (in IDR) 9M24 9M25 YoY (in IDR) 9M24 9M25 YoY Average Selling Sales Volume Total Sales Price Disposable & Disposable & Disposable & 1,128,113 1,246,690 10.5% 601 580 -3.5% 677,995,778 722,964,765 6.6% Consumables Consumab
Slide 25: Key Performance Ratios
Key Performance Ratios Key Ratios 2021 2022 2023 2024 9M 2024 9M 2025 Profitability Ratios Revenue Growth 11.6% -21.9% -0.1% 8.6% 7.7% 7.7% Gross Profit Margin 40.6% 35.1% 31.8% 33.1% 32.8% 33.9% EBITDA Margin 34.7% 25.0% 23.1% 21.6% 21.4% 21.6% Net Profit Margin 25.6% 16.8% 14.9% 17.2% 15.6% 17.4%
Slide 26: Corporate Highlights & Public Engagements
Corporate Highlights & Public Engagements Source: Company’s Social Media
Slide 27: Thank You
THANK YOU PT Jayamas Medica Industri Tbk (OMED IJ)
Slide 28: Contact Us
CONTACT US ir@onemed.co.id https://www.tokopedia.com/onemed corporate.secretary@onemed.co.id https://www.onemed.co.id/ https://shopee.co.id/onemed https://omed.idx
PT Jayamas Medica Industri — Investor Presentation (October 2025) on 6ix